 Outlook Therapeutics, Inc. OTLK the Company, a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has closed its previously-announced registered direct offering priced at-the-market under Nasdaq rules of 7,598,426 shares of its common stock, at a combined purchase price of 1.016 per share and associated unregistered warrant, for aggregate gross proceeds of approximately 7.72 million. The Company also issued to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 3,799,213 shares of its common stock. The warrants have an exercise price of 0.9535 per share of common stock, are exercisable on the date of issuance, and will expire four years following the date of issuance. 